Crinetics Pharmaceuticals’ Palsonify, approved by the FDA, offers a once-daily oral treatment for acromegaly patients ineligible for surgery or with inadequate surgical response. The therapy significantly lowers growth hormone levels with a favorable safety profile. Despite facing competition from established injectable drugs, Palsonify's approval represents a new oral therapy option for this rare hormonal disorder. The company’s stock surged post-approval, signaling market confidence.